As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
The Food and Drug Administration (FDA) has approved a transformational treatment for one of the most tragic of pediatric skin diseases. The first-of-its kind topical gene therapy for Epidermolysis ...
ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, ...
The patient has the Hallopeau-Siemens variant of dystrophic epidermolysis bullosa (EB). EB comprises a group of rare genetic states that are characterized by extremely fragile skin and recurrent ...
Epidermolysis bullosa (EB) forms three genetically different inherited disorders; they include simplex, junctional and dystrophic bullosa. All three types share some major features: genetic ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye. In 1999, I defined regenerative medicine as the collection of ...
Credit: Krystal Biotech. Vyjuvek is a topical HSV-1 vector-based gene therapy. The Food and Drug Administration (FDA) has approved Vyjuvek ™ (beremagene geperpavec-svdt) for the treatment of wounds in ...
Epidermolysis Bullosa: Types, Causes, Symptoms and Treatments: By Shreoshree Chakrabarty Epidermolysis Bullosa (EB) is a rare genetic disorder marked by extremely fragile skin that blisters or tears ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback